Valuation: NeoGenomics, Inc.

Market Cap 2.13B 1.84B 1.72B 1.58B 2.97B 203B 3.01B 20.18B 7.92B 102B 7.99B 7.82B 336B P/E 2026 *
-55.9x
P/E 2027 * -66.3x
Enterprise Value 2.13B 1.84B 1.72B 1.58B 2.97B 203B 3.01B 20.18B 7.92B 102B 7.99B 7.82B 336B EV / Sales 2026 *
2.65x
EV / Sales 2027 * 2.41x
Free-Float
96.14%
Yield 2026 *
-
Yield 2027 * -
1 day+6.49%
1 week+8.37%
Current month+8.37%
1 month+14.28%
3 months+82.69%
6 months+45.10%
Current year+40.90%
1 week 15.34
Extreme 15.34
16.6
1 month 13.05
Extreme 13.05
16.6
Current year 7.06
Extreme 7.065
16.6
1 year 5.64
Extreme 5.645
16.6
3 years 4.72
Extreme 4.72
21.22
5 years 4.72
Extreme 4.72
54.74
10 years 4.72
Extreme 4.72
61.57
Manager TitleAgeSince
Chief Executive Officer 65 2025-03-31
Director of Finance/CFO 57 2026-03-01
President 53 2025-03-31
Director TitleAgeSince
Chairman 64 2021-10-06
Director/Board Member 63 2017-07-18
Director/Board Member 69 2020-07-14
Date Insider Type Main position Quantity % Market Cap.
8/4/26 Sell

Controller/Auditor

-20,000 0.0154%
6/23/26 Free

Director

23,909 0.0184%
6/1/26 Fiscal year

Director

73,193 0.0562%
Change 5-day change 1-year change 3-year change Capi.($)
+6.49%+8.37%+187.67%+4.87% 2.13B
+21.37%+20.29%+128.31%+531.32% 46.26B
+0.83%+3.22%+22.78%+48.87% 25.88B
+0.04%+1.78%-20.11%-34.65% 7.76B
+6.20%+13.49%+37.80%+114.41% 5.69B
+0.19%+1.39%+20.23%+62.71% 3.39B
+10.76%+18.38%-27.25%+1,052.17% 2.3B
+11.67%+10.56%+30.24%+20.78% 2.02B
+3.35%+4.36%-5.60%-56.72% 1.99B
+3.62%+11.34%+26.45%-11.19% 1.84B
Average +6.45%+9.34%+40.05%+173.26% 9.93B
Weighted average by Cap. +11.30%+12.19%+71.40%+289.87%

Financials

2026 *2027 *
Net sales 804M 696M 650M 596M 1.12B 76.53B 1.14B 7.62B 2.99B 38.36B 3.02B 2.95B 127B 885M 765M 715M 656M 1.23B 84.21B 1.25B 8.39B 3.29B 42.21B 3.32B 3.25B 140B
Net income -38.73M -33.5M -31.29M -28.7M -53.98M -3.69B -54.84M -367M -144M -1.85B -145M -142M -6.11B -33.19M -28.71M -26.81M -24.59M -46.25M -3.16B -46.99M -315M -123M -1.58B -125M -122M -5.23B
Net Debt - -
Logo NeoGenomics, Inc.
NeoGenomics, Inc. is a cancer diagnostics company specializing in cancer genetics testing and information services. The Company offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing, interpretation and consultative services, molecular and NGS testing, comprehensive technical and professional services offering, clinical trials and research, validation laboratory services, and oncology data solutions. It operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics, Fluorescence In-Situ Hybridization (FISH), Flow cytometry, Molecular testing and others.
Employees
2,500
Date Price Change Volume
26-08-07 US$16.57 +6.49% 1,346,624
26-08-06 US$15.56 -1.08% 1,906,521
26-08-05 US$15.73 -3.44% 1,824,488
26-08-04 US$16.29 +2.84% 2,707,900
26-08-03 US$15.84 +3.60% 2,974,026
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
16.57USD
Average target price
19.72USD
Spread / Average Target
+19.02%

Quarterly revenue - Rate of surprise